Mechanism of Action
GLP2R Signaling and Intestinal Trophism
GLP2R is expressed on subepithelial myofibroblasts (primary), enteric neurons, and some epithelial cells. Gs-coupled GLP2R activation raises cAMP and activates downstream growth factor secretion (IGF-1, EGF, KGF) from myofibroblasts, which then act paracrine on intestinal epithelial stem cells (LGR5+) to stimulate crypt proliferation and villus elongation. Net effect: increased mucosal surface area, enhanced absorptive capacity, and restored barrier integrity.
Intestinal Barrier and Anti-Inflammatory Effects
GLP-2 enhances tight junction protein expression (claudin-3, occludin, ZO-1), reducing intestinal permeability. In Crohn disease and radiation enteritis models, GLP-2 reduces mucosal inflammation and promotes mucosal healing. GLP-2 also reduces gastric acid secretion (pro-absorptive), slows gastric emptying, and reduces intestinal motility, increasing contact time for nutrient absorption.
Research Summary
Short Bowel Syndrome (Teduglutide)
FDA ApprovedSTEPS Phase 3 trial (teduglutide in SBS-IF): 63% of patients achieved >20% reduction in parenteral nutrition volume at 24 weeks vs 30% placebo. Two-year extension: 54% achieved complete enteral autonomy. Teduglutide is the only FDA-approved drug promoting intestinal adaptation, enabling more patients to wean off PN. Approved for adults (2012) and pediatric patients (2019, down to 1 year of age).
Crohn's Disease
Phase 2GLP-2 analogs reduce Crohn disease activity scores, improve mucosal healing, and reduce inflammatory markers in Phase 2 trials. The intestinal trophic and anti-inflammatory mechanisms are particularly relevant for inflammatory bowel disease, where mucosal barrier dysfunction drives disease activity.
Necrotizing Enterocolitis Prevention
Active ResearchGLP-2 is a critical factor in intestinal maturation of premature neonates. Low GLP-2 correlates with NEC risk. GLP-2 analog administration in premature animal models reduces NEC incidence. Phase 2 trials in premature infants are being designed to test whether GLP-2 supplementation can prevent NEC.
Calculate your GLP-2 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Short bowel syndrome (teduglutide) | 0.05 mg/kg SC once daily; maximum 2.5 mg/day in most adults | Once daily | Subcutaneous (abdomen, thigh, arm) |
| Intestinal trophism research | 10-100 mcg/kg SC daily in rodent intestinal adaptation models | Daily | Subcutaneous |
Monitor intestinal polyps -- GLP-2R stimulation may accelerate growth of pre-existing intestinal adenomas; colonoscopy required before and during teduglutide therapy.
Interactions
Safety Profile
Teduglutide: most common adverse effects are GI (abdominal pain 30%, nausea 18%, injection site reactions 22%, vomiting 12%). Fluid overload from enhanced intestinal absorption may occur, requiring PN volume adjustment. Important: GLP-2 trophic effects on intestinal epithelium risk accelerating growth of pre-existing colorectal polyps/adenomas -- mandatory colonoscopy at baseline and yearly during treatment. Contraindicated in patients with active gastrointestinal malignancy. Intestinal obstruction has been reported; monitor closely. Gallbladder and biliary tract disease (sludge, stones) observed.
References
- [1]Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS). Gastroenterology. 2012;143(6):1473-1481.
- [2]Drucker DJ, et al. Regulation of the biology of GLP-2 in human health and disease. Nat Rev Endocrinol. 2019;15(12):694-706.